A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Public ClinicalTrials.gov record NCT06215118. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. Part 2 will look at the correct amount of this combination that can be given to patients with relapsed or refractory multiple myeloma. Myeloma is a type of cancer that begins in plasma cells (white blood cells that produce antibodies). Refractory means a disease or condition that does not respond to treatment. Relapsed means the return of a disease after a period of improvement. All study medicines are given in cycles that last 28 days. Everyone taking part in this study will receive elranatamab as a shot under the skin. Iberdomide will be taken by mouth once a day for 21 days over a 28-day cycle. Participants will receive study medicine until: * their disease progresses or, * they experience unacceptable side effects or, * they choose to no longer take part in the study. The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and can be used for multiple myeloma treatment.
Study identification
- NCT ID
- NCT06215118
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 20, 2024 (Actual)
- Primary completion
- Nov 16, 2027 (Estimated)
- Completion
- Oct 15, 2028 (Estimated)
- Last update posted
- Sep 15, 2026
2024 – 2028
United States locations
- U.S. sites
- 34
- U.S. states
- 11
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center | Coral Gables | Florida | 33146 | — |
| University of Miami Hospital and Clinics Deerfield Beach | Deerfield Beach | Florida | 33442 | — |
| Sylvester Comprehensive Cancer Center- Doral | Doral | Florida | 33166 | — |
| Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| University of Miami Hospital and Clinics | Miami | Florida | 33136 | — |
| Sylvester Comprehensive Cancer Center Kendall | Miami | Florida | 33176 | — |
| Sylvester Comprehensive Cancer Center Plantation | Plantation | Florida | 33324 | — |
| Emory University Hospital Midtown | Atlanta | Georgia | 30308 | — |
| Emory University Hospital | Atlanta | Georgia | 30322 | — |
| Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Indiana CTSI Clinical Research Center (ICRC) | Indianapolis | Indiana | 46202 | — |
| Indiana University Health University Hospital | Indianapolis | Indiana | 46202 | — |
| Indiana University Melvin and Bren Simon Comprehensive Cancer Center (IUSCCC) | Indianapolis | Indiana | 46202 | — |
| University of Maryland | Baltimore | Maryland | 21201 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute - Chestnut Hill | Newton | Massachusetts | 02459 | — |
| University of Massachusetts Chan Medical School | Worcester | Massachusetts | 01655 | — |
| Methodist Hospital | Omaha | Nebraska | 68114 | — |
| Oncology Hematology West P.C. dba Nebraska Cancer - Methodist | Omaha | Nebraska | 68114 | — |
| Oncology Hematology West P.C. dba Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| MSK Basking Ridge | Basking Ridge | New Jersey | 07920 | — |
| MSK Monmouth | Middletown | New Jersey | 07748 | — |
| MSK Bergen | Montvale | New Jersey | 07645 | — |
| MSK Commack | Commack | New York | 11725 | — |
| MSK Westchester | Harrison | New York | 10604 | — |
| Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy | Long Island City | New York | 11101 | — |
| Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). | New York | New York | 10021 | — |
| Memorial Sloan Kettering Cancer Center - Main Campus | New York | New York | 10065 | — |
| MSK Nassau | Uniondale | New York | 11553 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
| University of Washington | Seattle | Washington | 98195 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06215118, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 15, 2026 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06215118 live on ClinicalTrials.gov.